Breaking News Instant updates and real-time market news.

MYL

Mylan

$29.87

(0.00%)

, XLY

Consumer Discretionary Sector SPDR

$104.26

(0.00%)

09:40
01/09/19
01/09
09:40
01/09/19
09:40

Unusually active option classes on open January 9th

Unusual total active option classes on open include: Mylan (MYL), Consumer Discretionary Sector SPDR ETF (XLY), Snap Inc. (SNAP), EBay (EBAY), Canopy Growth (CGC), Wynn Resorts (WYNN), US Steel (X), Chesapeake (CHK), Western Digital (WDC), and Alibaba (BABA).

MYL

Mylan

$29.87

(0.00%)

XLY

Consumer Discretionary Sector SPDR

$104.26

(0.00%)

SNAP

Snap

$6.40

(0.00%)

EBAY

eBay

$30.01

(0.00%)

CGC

Canopy Growth

$29.63

(0.00%)

WYNN

Wynn Resorts

$112.90

(0.00%)

X

U.S. Steel

$20.69

(0.00%)

CHK

Chesapeake

$2.45

(0.00%)

WDC

Western Digital

$38.11

(0.00%)

BABA

Alibaba

$146.88

(0.00%)

  • 24

    Jan

  • 31

    Jan

  • 18

    Feb

  • 03

    Mar

  • 04

    Mar

MYL Mylan
$29.87

(0.00%)

12/18/18
BERN
12/18/18
NO CHANGE
Target $288
BERN
Market Perform
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks
Bernstein analyst Aaron Gal earlier today lowered his price target for Biogen (BIIB) to $288 from $341 while keeping a Market Perform rating on the shares. The Biogen "debate" revolves primarily around three elements: the durability of the existing franchises, the value of the company's Alzheimer's opportunity, and the potential of the pipeline to generate new drugs, Gal wrote in a research note. He believes the stock's current risk/reward balance "captures these dynamics." In Q1 of 2019, however, Biogen is facing "two significant risks," says the analyst. These are the inter partes review institution decision on its biggest drug, Tecfidera, and futility analyses of amyloid beta drugs - Roche's (RHHBY) crenezumab and potentially Biogen's own aducanumab, according to Gal. The analyst views Biogen's near-term risk/reward as "sharply negative." If a review of Tecfidera is instituted and one of the amyloid beta trials is stopped for futility, the stock "can easily" trade $100 per share lower, Gal believes. Even if one of these events goes against the company, the analyst thinks the Biogen can drop $30-$80 per share. On the other hand, passing both risks will likely only have "moderate upside" of around $30 per share as "both are assumed to be positive in sell-side consensus," Gal writes. He keeps a Market Perform rating on Biogen, which is down 7%, or $21.45, to $291.66 in afternoon trading.
12/18/18
PIPR
12/18/18
NO CHANGE
Target $400
PIPR
Overweight
Piper says Biogen weakness on Tecfidera patent concerns a buying opportunity
Piper Jaffray analyst Christopher Raymond attributes today's weakness in Biogen (BIIB) shares to a competitor's research note that raised concerns about Mylan's (MYL) IPR challenge of Tecfidera's '514 dosing patent. While acknowledging that a worst case scenario does remove about $50 per share from his sum-of-the-parts valuation for Biogen, Raymond said his read of the current case, along with the fact that the '514 patent previously survived Forward Pharma's 2014 interference claim and Hayman Capital's IPR in 2015, lead him to view such scenario as "very low probability." The analyst, who views the weakness as a buying opportunity, keeps an Overweight rating and $400 price target on Biogen shares, which are down 7% to $291.31 in afternoon trading.
11/29/18
MAXM
11/29/18
INITIATION
Target $3
MAXM
Buy
Agile Therapeutics initiated with a Buy at Maxim
Maxim analyst Caroline Palomeque initiated Agile Therapeutics (AGRX) with a Buy rating and a price target of $3, saying that she likes the risk-reward on the stock as the company approaches an NDA resubmission for its Twirla - a low-dose combined hormone contraceptive transdermal patch. The analyst cites the large potential market opportunity for the product, with combined hormone contraceptive market generating about $4B and the current patch availability being limited to Mylan's (MYL) Xulane. Palomeque further contends that Twirla "offers a low-dose, safer estradiol, potentially with no 'black box' warning."
11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
XLY Consumer Discretionary Sector SPDR
$104.26

(0.00%)

SNAP Snap
$6.40

(0.00%)

01/04/19
GSCO
01/04/19
DOWNGRADE
Target $6
GSCO
Neutral
Snap downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Heath Terry downgraded Snap (SNAP) to Neutral and lowered his price target for the shares to $6 from $10. The stock closed yesterday down 11c to $5.68. The analyst believes Snap's sequential user declines are likely to continue in Q4. In order to generate a Twitter-like turnaround, the company will have to return to user growth, Terry tells investors in a research note. However, he sees uncertainty around Snap's new Android app and its ability to reaccelerate daily active user growth, particularly in the midst of growing competition from Facebook's (FB) Instagram and ByteDance's Tik Tok. The analyst, nonetheless, still believes there is "significant value" in Snap's users.
01/04/19
01/04/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Skyworks (SWKS) downgraded to Neutral from Buy at Nomura Instinet with analyst Krysten Sciacca saying after Apple's (AAPL) profit warning, she believes growth headwinds from macro and trade uncertainty, as well as weak unit demand at the company's largest customers, will persist in 2019. 2. Snap (SNAP) downgraded to Neutral from Buy at Goldman Sachs with analyst Heath Terry saying he believes Snap's sequential user declines are likely to continue in Q4. 3. Fortinet (FTNT) double downgraded to Sell from Buy at Goldman Sachs with analyst Gabriela Borges saying the drivers of Fortinet's share gain and margin expansion are now better understood, with consensus 2019 estimates having been revised up over the past 12 months. 4. eBay (EBAY) downgraded to Neutral from Buy at Goldman Sachs with analyst Heath Terry saying he sees better opportunities with other names in Internet given uncertainty around eBay's growth and margin expansion, specifically the company's ability to deliver low-to-mid single digit growth on reduced ad spend. 5. Halcon Resources (HK), Chesapeake (CHK), and Southwestern Energy (SWN) were downgraded to Underperform from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/19
PIVT
01/07/19
DOWNGRADE
Target $6
PIVT
Hold
Snap downgraded to Hold from Buy at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Snap to Hold and lowered his price target for the shares to $6 from $8. Concerns around employee churn are playing out, Wieser tells investors in a research note. Significant additional stock grants to key employees may be necessary despite their diluting effects, adds the analyst. He believes this represents an incremental downside risk for investors to consider.
01/07/19
01/07/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Skyworks (SWKS) downgraded to Perform from Outperform at Oppenheimer with analyst Rick Schafer citing the current "semiconductor correction" as well as "continued negative" smartphone news. 2. Snap (SNAP) downgraded to Hold from Buy at Pivotal Research with analyst Brian Wieser saying concerns around employee churn are playing out. 3. PNC Financial (PNC) downgraded to Neutral from Buy at Goldman Sachs with analyst Richard Ramsden saying commercial loan growth has fallen 7 percentage points and is likely to track industry growth rates more closely from here. 4. Quarterhill (QTRH) downgraded to Hold from Buy at Canaccord. 5. Urban Outfitters (URBN) downgraded to Neutral from Overweight at JPMorgan with analyst Matthew Boss saying he sees a "flattish comp downside scenario neutralizing the risk/reward profile." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
EBAY eBay
$30.01

(0.00%)

12/21/18
BARD
12/21/18
NO CHANGE
BARD
U.K. 'yellow flags' could limit Q4 upside for Amazon and PayPal, says Baird
While e-commerce trends in North America remain healthy, there are enough "yellow flags" in the U.K./Europe data to make risks elevated for e-commerce companies with international exposure, Baird analyst Colin Sebastian tells investors in a research note. Reports and commentary from U.K. online spending sources, retailer Asos, FedEx (FDX), Visa (V), and smaller players suggest December e-commerce spending may be tracking below expectations in the region, says the analyst. He points out that PayPal (PYPL), eBay (EBAY) and Amazon.com (AMZN) are most exposed to European e-commerce among the companies he covers. Sebastian believes the possible U.K. slowdown could limit revenue and margin upside for those companies in Q4.
12/26/18
BARD
12/26/18
NO CHANGE
BARD
Baird names Amazon, Alphabet among best internet stocks to own for rebound
Baird analyst Colin Sebastian pointed out in a note to investors before the open that the number of searches on Google for the term "recession" has more than doubled since October, hitting a recent peak in early December. However, he thinks it is reasonable to consider a more optimistic outcome, namely a rebound, and looked back at the past four market "corrections" to see which stocks in large-cap internet fared. In each of the six-month periods he analyzed, Activision (ATVI), Facebook (FB) and Alphabet (GOOGL) traded higher with the lowest standard deviations in the group, Sebastian noted, adding that he thinks lingering overhangs on Facebook shares could dampen its recovery this time around. Amazon (AMZN) was the best overall performer, while eBay (EBAY) was the laggard, each with higher standard deviations, Sebastian added. Overall, he named Activision, Alphabet and Amazon as his "AAA" best bets in a rebound scenario.
01/04/19
GSCO
01/04/19
DOWNGRADE
Target $32
GSCO
Neutral
eBay downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Heath Terry downgraded eBay to Neutral and lowered his price target for the shares to $32 from $34. The analyst sees better opportunities with other names in Internet given uncertainty around eBay's growth and margin expansion, specifically the company's ability to deliver low-to-mid single digit growth on reduced ad spend. eBay has tried unsuccessfully to reaccelerate growth for sustained periods, and uncertainty around the elasticity of marketing spend could also challenge margin expansion and pressure its earnings growth, Terry tells investors in a research note.
CGC Canopy Growth
$29.63

(0.00%)

01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
01/09/19
PIPR
01/09/19
INITIATION
PIPR
Overweight
Piper Jaffray rolls out bullish research coverage on Canopy Growth, Tilray
Piper Jaffray analyst Michael Lavery initiated coverage of Canopy Growth (CGC) and Tilray (TLRY) with Overweight ratings and price targets of $40 and $90, respectively. The analyst believes the global Cannabis market has the potential to reach $250B-$500B over the long term and $15B-$50B in the near term. The industry's long-term growth opportunities are significant, both from transitioning illicit trade to legal sales and from transitioning sales in health and wellness categories to cannabidiol-infused products, Lavery tells investors in a research note. The analyst expects recreational use to source from illicit trade and alcohol, medical use to source from other medical treatments, and non-psychoactive CBD-infused cannabis products to source users from food, beverage, and personal care categories. Over 25 countries have legal marijuana use today, he points out. Lavery believes federal legalization in the U.S. could potentially come in the next five years. Further, the analyst expects capital flow into the sector will likely continue.
01/09/19
PIPR
01/09/19
INITIATION
Target $40
PIPR
Overweight
Canopy Growth initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery started Canopy Growth with an Overweight rating and $40 price target. The analyst expects "strong" sales growth from the company, driven by "strong sustainable category momentum." Canopy's capacity advantages, beverage partnership, and balance sheet position it well over the near-term, Lavery tells investors in a research note. He also believes the company's clinical trials and intellectual property should add competitive advantages longer term.
01/04/19
WELS
01/04/19
NO CHANGE
Target $260
WELS
Outperform
Constellation 'one of the most attractive stocks' in Staples, says Wells Fargo
Wells Fargo analyst Bonnie Herzog reiterated an Outperform rating and $260 price target on Constellation Brands (STZ), telling investors in a research note that she believes Constellation is one of the most attractive stocks in Staples, given scarcity of growth across the group and the pullback, which she says is "unjustified." While she expects Constellation to lower FY19 EPS guidance to reflect 25c-30c of interest expense from the increased stake in Canopy Growth (CGC), Herzog believes Q3 results may surprise to the upside based on strong performance in Nielsen scanner data through December and potential beer margin upside from lower marketing investments. She sees Q3 results as a potential positive catalyst and encourages long-term investors to accumulate positions in the stock.
WYNN Wynn Resorts
$112.90

(0.00%)

12/03/18
MSCO
12/03/18
NO CHANGE
MSCO
Overweight
Xi-Trump truce should ease some Macau concerns, says Morgan Stanley
Morgan Stanley analyst Thomas Allen believes that the constructive outcome from the G-20 meeting of Presidents Trump and Xi should be a positive for both Las Vegas Sands (LVS) and Wynn Resorts (WYNN), as he believes a thawing of trade tensions should ease some concerns around Macau concession renewals. Macau stocks have also been weighed down by slowing demand and concerns around the China consumption backdrop, but there have been positive updates on that front too, said Allen, who noted that Las Vegas Sands continues to be his preferred play on Macau. He keeps Overweight ratings on Las Vegas Sands and MGM Resorts (MGM), but does not view MGM as the same type of China proxy given its less than 20% Macau mix. Allen keeps an Equal Weight rating on Wynn shares.
01/07/19
DBAB
01/07/19
NO CHANGE
DBAB
Wynn, Caesars best large-cap Gaming stocks for 2019, says Deutsche Bank
Deutsche Bank analyst Carlo Santarelli says Wynn Resorts (WYNN) and Caesars Entertainment (CZR) are the best ways to play the large-cap Gaming space in 2019. Given current valuations and fundamental expectations "that seemingly accompany those valuations," the analyst is constructive on the larger-cap Gaming names and sees a bias to the upside in the stocks.
11/21/18
DBAB
11/21/18
NO CHANGE
DBAB
Buy
Wynn Resorts shares set up well to outperform, says Deutsche Bank
Deutsche Bank analyst Carlo Santarelli believes Wynn Resorts management was prudent to reset the bar lower "during a period in which heroism is hardly being rewarded in gaming." The analyst finds the guidance conservative, which he thinks sets up shares of Wynn Resorts well to outperform, relative to peers. Santarelli keeps a Buy rating on the name.
12/05/18
UBSW
12/05/18
NO CHANGE
UBSW
UBS now sees Macau gross gaming revenue declining in 2019
UBS analyst Robin Farley lowered her 2019 Macau gross gaming revenue forecast to down 1% from up 5% previously. Her 2020 GGR estimate is now up 4% from a prior estimate of up 8%. Despite better than expected revenue in November, likely due to hold fluctuations, the lower estimates are driven by weaker VIP and premium demand amid heightened risk to the macroeconomic outlook in China, Farley tells investors in a research note partially titled "More Visitors Spending Less." She raised her price target for Neutral-rated Wynn Resorts (WYNN) to $113 from $108 while lowering her targets for Neutral-rated MGM Resorts (MGM) to $30 from $32 and Neutral-rated Melco Resorts & Entertainment (MLCO) to $19.50 from $21.60. The analyst also keeps a Neutral rating on Las Vegas Sands (LVS).
X U.S. Steel
$20.69

(0.00%)

01/09/19
SBSH
01/09/19
DOWNGRADE
Target $23
SBSH
Neutral
U.S. Steel downgraded to Neutral from Buy at Citi
Citi analyst Alexander Hacking downgraded U.S. Steel to Neutral and lowered his price target for the shares to $23 from $40.
01/08/19
COWN
01/08/19
INITIATION
Target $22
COWN
Market Perform
U.S. Steel initiated with a Market Perform at Cowen
Cowen analyst Tyler Kenyon initiated U.S. Steel with a Market Perform and $22 price target.
01/08/19
01/08/19
DOWNGRADE
Target $24

Neutral
U.S. Steel downgraded to Neutral on downside risk at Credit Suisse
As previously reported, Credit Suisse analyst Curt Woodworth downgraded U.S. Steel to Neutral from Outperform owing to more severe downside risk to earnings and free cash flow for 2019. While the stock could rally in Q1 as HRC fundamentals improve, the analyst believes the risk/reward profile has shifted to a neutral level given the sharp downturn in sheet prices at the same time capex is moving higher. Woodworth also argues that U.S. Steel will face more intense competition on the about 60% of U.S. volume tied to spot or quarterly terms as new EAF capacity drives the U.S. sheet market toward a clear oversupply position by 2021/2022. The analyst lowered his price target on the shares to $24 from $40.
01/08/19
FBCO
01/08/19
DOWNGRADE
FBCO
Neutral
U.S. Steel downgraded to Neutral from Outperform at Credit Suisse
CHK Chesapeake
$2.45

(0.00%)

12/07/18
12/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Secureworks (SCWX) downgraded to Sector Perform from Outperform at RBC Capital and to Neutral from Outperform at First Analysis. 2. Methanex (MEOH) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying he is now more cautious on the Chemicals space and he expects recession risk signals to continue emerging over the next few quarters. 3. Expeditors (EXPD) downgraded to Sell from Neutral at Goldman Sachs with analyst Matthew Reustle saying he sees "headwinds on the horizon" amid continued deceleration in the company's airfreight business and structural headwinds in its ocean freight business. 4. Chesapeake (CHK) downgraded to Underweight from Neutral at JPMorgan while Devon Energy (DVN) was downgraded to Neutral from Overweight. 5. Momo (MOMO) downgraded to Equal Weight from Overweight at Morgan Stanley and to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/19
BOFA
01/04/19
DOWNGRADE
Target $3.5
BOFA
Underperform
Chesapeake downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill Lynch analysts led by Doug Leggate downgraded a number of U.S. Oil and Gas stocks, stating that he prefers "discipline over growth" among large caps. Leggate and the team acknowledge a recovery in oil prices could lead to material upside, but views volatility as the biggest challenge as too many stocks are competing for shrinking investor dollars. He sees gas names remaining challenged by the falling incremental cost for U.S. natural gas and downgraded Chesapeake to Underperform from Neutral given the headwinds he sees for gas weighted E&P names. Leggate and the team lowered their price target for Chesapeake to $3.50 from $6.00.
12/20/18
SOCO
12/20/18
DOWNGRADE
SOCO
Underweight
Chesapeake downgraded to Underweight from Overweight at Capital One
WDC Western Digital
$38.11

(0.00%)

12/13/18
DBAB
12/13/18
INITIATION
DBAB
Seagate, Western Digital resumed with Hold ratings at Deutsche Bank
Deutsche Bank analyst Sidney Ho resumed coverage of both Seagate Technology (STX) and Western Digital (WDC) with Hold ratings, and price targets of $42 and $45, respectively. The analyst said in a note partially titled "Cloudy near term, Cloud is also the future" that while hard disk drive, or HDD, is a mature industry, several interesting trends have emerged. First, nearline HDDs that are suited for mass storage in cloud data centers could drive 60%+ of the industry revenue by 2022 with above industry average margins. Second, technology innovations in the next 5-10 years could continue to drive cost improvements in the HDD industry. Third, while declining NAND flash memory prices have led to rising adoption of solid state drives, or SSDs, the cannibalization focuses on PCs and mission-critical enterprise applications, while nearline HDDs appear to be more immune. The analyst concluded that "while HDD revenues appear to be on a slow decline, changing mix will likely drive better profitability."
12/13/18
DBAB
12/13/18
INITIATION
Target $45
DBAB
Hold
Western Digital resumed with a Hold at Deutsche Bank
Deutsche Bank analyst Sidney Ho resumed coverage of Western Digital with a Hold rating and $45 price target. The analyst sees "cloudy" near-term fundamentals for the hard disk drive industry.
12/11/18
GSCO
12/11/18
NO CHANGE
GSCO
Goldman Sachs lowers price targets on Micron, Western Digital after Asia tour
Goldman Sachs analyst Toshiya Hari lowered his price target on Neutral-rated Micron (MU) to $44 from $45 and on Western Digital (WDC) to $41 from $47 while also lowering his EPS view on Nvidia (NVDA) to $6.80 from $7.40 and AMD (AMD) to 50c from 52c following his tech/semi's-focused tour in Asia that included meetings with over 25 supply chain companies. The analyst claims that the findings and datapoints from the discussions were "mostly negative, especially those related to memory, HDDs, semi cap, GPUs, and smartphones". Hari sees the near-term server demand as "weak" with flattish Q1, and AI adoption being lower than expected in the supply chain. The analyst notes that industry participants saw AMD with continued market share gains as it launches its EPYC 2 products and the cadence for Intel (INTC) platform slowing as its upgrade cycle lengthens to three years from two. For Nvidia, the analyst also expects the ongoing inventory correction to spill into the April quarter.
01/02/19
BNCH
01/02/19
NO CHANGE
BNCH
Hold
Western Digital FY19 estimates lowered at Benchmark on falling NAND prices
Benchmark analyst Mark Miller lowered his FY19 estimates for Western Digital due to declining NAND prices, which he expects to persist during the first half of 2019. While he believes the decline in Western's shares in the past six months factors in the ongoing price declines, he still only projects a 5% year-over-year bottom line gain and keeps a Hold rating on the stock.
BABA Alibaba
$146.88

(0.00%)

12/13/18
12/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) assumed with a Buy at Mizuho. 2. Molson Coors (TAP) and Keurig Dr Pepper (KDP) were initiated with a Buy at UBS, while PepsiCo (PEP) and Constellation Brands (STZ) were initiated with a Neutral, and Monster Beverage (MNST) and Boston Beer (SAM) were initiated with a Sell. 3. SeaSpine (SPNE) initiated with an Outperform at Wells Fargo. 4. XPO Logistics (XPO) initiated with a Buy at SunTrust. 5. Enanta (ENTA) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/18
MZHO
12/12/18
INITIATION
Target $200
MZHO
Buy
Alibaba assumed with a Buy at Mizuho
Mizuho Securities analyst James Lee assumed coverage of Alibaba with a Buy rating and $200 price target. The analyst views the company as a "defensive play" for China's uncertain macro outlook. He believes the stock is only pricing in the core e-commerce unit and that Alibaba's new investments, like Cloud, Food Delivery, Online Video, and Payments, are "free call options."
11/19/18
11/19/18
DOWNGRADE
Target $26

Hold
JD.com downgraded to Hold on China slowdown, competition at Stifel
As previously reported, Stifel analyst Scott Devitt downgraded JD.com (JD) to Hold from Buy as he believes the slowing economy in China, coupled with e-commerce competition, will keep pressuring the company's core operating results. After JD.com reported Q3 revenue that missed the Street's forecast and its annual active customers fell quarter-over-quarter, Devitt cut his price target on the shares to $26 from $32. He prefers Alibaba (BABA) on a potential turnaround in China sentiment, Devitt added.
11/13/18
MKMP
11/13/18
NO CHANGE
Target $245
MKMP
Buy
Alibaba price target lowered to $245 from $270 at MKM Partners
MKM Partners analyst Rob Sanderson lowered his price target on Alibaba to $245, saying the bulk of his revision comes from the "lower profit from the core commerce segment as management postpones monetization efforts and braces for a possible economic slow-down". The analyst also points to the perceived "desperation" of the Chinese central bank in setting a 30% target for private enterprise loans as part of the banking system's total lending. Longer term, Sanderson keeps his Buy rating on Alibaba based on his confidence that the slowing economy will create separation for market leaders and that the company's recent execution appears to be better than in the last slowdown.

TODAY'S FREE FLY STORIES

ETFC

E-Trade

$48.89

0.65 (1.35%)

09:25
02/23/19
02/23
09:25
02/23/19
09:25
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CAT

Caterpillar

$138.77

-0.08 (-0.06%)

, XRX

Xerox

$31.50

0.16 (0.51%)

08:29
02/23/19
02/23
08:29
02/23/19
08:29
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CAT

Caterpillar

$138.77

-0.08 (-0.06%)

XRX

Xerox

$31.50

0.16 (0.51%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.81

0.02 (0.14%)

F

Ford

$8.71

(0.00%)

GM

General Motors

$39.98

0.35 (0.88%)

HMC

Honda

$28.17

0.43 (1.55%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$121.84

0.66 (0.54%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$31.51

-0.62 (-1.93%)

LUV

Southwest

$53.62

-0.69 (-1.27%)

VZ

Verizon

$56.95

0.81 (1.44%)

TMUS

T-Mobile

$73.17

-0.09 (-0.12%)

T

AT&T

$31.15

0.32 (1.04%)

NOK

Nokia

$6.21

0.06 (0.98%)

ERIC

Ericsson

$9.51

0.285 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 03

    Mar

  • 03

    Mar

  • 04

    Mar

  • 11

    Mar

  • 13

    Mar

  • 20

    Mar

  • 27

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

AIMT

Aimmune

$23.70

0.73 (3.18%)

, AZN

AstraZeneca

$40.95

0.515 (1.27%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
The American Academy of Asthma, Allergy & Immunology to hold annual meeting »

AAAAI Annual Meeting 2019…

AIMT

Aimmune

$23.70

0.73 (3.18%)

AZN

AstraZeneca

$40.95

0.515 (1.27%)

TEVA

Teva

$17.28

0.03 (0.17%)

NVS

Novartis

$90.77

0.26 (0.29%)

DNA

Bought by RHHBY

$0.00

(0.00%)

SHPG

Shire

$0.00

(0.00%)

REGN

Regeneron

$422.43

3.77 (0.90%)

SNY

Sanofi

$41.20

-0.13 (-0.31%)

ALK

Alaska Air

$62.35

-0.48 (-0.76%)

ABT

Abbott

$76.40

1.26 (1.68%)

CVS

CVS Health

$62.00

-0.33 (-0.53%)

KALV

KalVista

$20.74

-0.04 (-0.19%)

BCRX

BioCryst

$8.99

0.32 (3.69%)

OPTN

Optinose

$7.31

0.02 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 04

    Mar

  • 04

    Mar

  • 04

    Mar

  • 07

    Mar

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

  • 18

    May

ETFC

E-Trade

$48.89

0.65 (1.35%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

TEN

Tenneco

$36.29

0.76 (2.14%)

16:48
02/22/19
02/22
16:48
02/22/19
16:48
Earnings
Tenneco sees FY19 revenue growth up 4%-5%, consensus $4.65B »

The company expects 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.